ArticleScientific reports2025
Machine learning driven multiomics analysis identifies disulfidptosis associated molecular subtypes in ovarian cancer.
Article in Scientific reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Disulfidptosis: Mechanisms, evidence boundaries, and translational opportunities.Redox biology · 2026Review
- The tumor microenvironment: a dynamic ecosystem and therapeutic nexus in modern oncology.Frontiers in pharmacology · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
Abstract
Precision oncology enables molecularly guided cancer therapy through multi-omics profiling, AI-driven classification, and biomarker-targeted interventions. Disulfidptosis has emerged as a promising therapeutic target, yet no ovarian cancer classification system currently incorporates this mechanism. The sequencing data of the samples in this study were obtained from TCGA and GEO databases. We analyzed 76 genes associated with disulfidptosis and performed consensus clustering based on their expression profiles to stratify the samples into two molecular subtypes. Differentially expressed genes (DEGs) were identified by comparing ovarian cancer tissues with normal samples. LASSO regression and random forest algorithms were then applied to screen marker genes that significantly influenced the clustering outcome. Ultimately, Ten disulfidptosis-related genes were ultimately selected to construct the predictive model. Single-cell sequencing was employed to characterize the tumor-specific expression patterns of key biomarkers. Digital spatial pathology analysis precisely mapped therapeutic target regions within tumor architectures. Immunohistochemical validation ultimately yielded clinically translatable biomarkers with diagnostic and therapeutic potential. Analysis of 76 disulfidptosis-related genes in ovarian cancer (OV) identified two molecular subtypes with distinct genomic profiles, tumor microenvironment characteristics, m6A regulator expression patterns, and clinical outcomes. Subgroup 1 showed copy number gains and immunosuppression, while Subgroup 2 exhibited higher tumor mutational burden (TMB) and immune activation. Subgroup 2 exhibited significantly higher immune infiltration, along with upregulated immune checkpoints. A 10-gene signature and CNN+GRU classifier robustly stratified patients. Single-cell and spatial transcriptomics confirmed epithelial-specific overexpression of key genes. This study identified a 10-gene signature related to disulfidptosis that is associated with distinct tumor microenvironment features, molecular heterogeneity, m6A modification patterns, and immune infiltration characteristics in ovarian cancer. Through multi-omics analyses-including single-cell and spatial transcriptomics-along with protein-level validation, our findings provide insights into the molecular landscape of ovarian cancer and suggest potential targets for future investigation into subtype-specific treatment strategies. All relevant code and analysis pipelines are publicly available at https://github.com/jinqy-lzu/Molecular_Subgroups_OV.git .
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.